Jiraskova Petra, Gazak Radek, Kamenik Zdenek, Steiningerova Lucie, Najmanova Lucie, Kadlcik Stanislav, Novotna Jitka, Kuzma Marek, Janata Jiri
Institute of Microbiology - Academy of Sciences of the Czech Republic Prague, Czech Republic.
Front Microbiol. 2016 Mar 7;7:276. doi: 10.3389/fmicb.2016.00276. eCollection 2016.
Structurally different and functionally diverse natural compounds - antitumour agents pyrrolo[1,4]benzodiazepines, bacterial hormone hormaomycin, and lincosamide antibiotic lincomycin - share a common building unit, 4-alkyl-L-proline derivative (APD). APDs arise from L-tyrosine through a special biosynthetic pathway. Its generally accepted scheme, however, did not comply with current state of knowledge. Based on gene inactivation experiments and in vitro functional tests with recombinant enzymes, we designed a new APD biosynthetic scheme for the model of lincomycin biosynthesis. In the new scheme at least one characteristic in each of five final biosynthetic steps has been changed: the order of reactions, assignment of enzymes and/or reaction mechanisms. First, we demonstrate that LmbW methylates a different substrate than previously assumed. Second, we propose a unique reaction mechanism for the next step, in which a putative γ-glutamyltransferase LmbA indirectly cleaves off the oxalyl residue by transient attachment of glutamate to LmbW product. This unprecedented mechanism would represent the first example of the C-C bond cleavage catalyzed by a γ-glutamyltransferase, i.e., an enzyme that appears unsuitable for such activity. Finally, the inactivation experiments show that LmbX is an isomerase indicating that it transforms its substrate into a compound suitable for reduction by LmbY, thereby facilitating its subsequent complete conversion to APD 4-propyl-L-proline. Elucidation of the APD biosynthesis has long time resisted mainly due to the apparent absence of relevant C-C bond cleaving enzymatic activity. Our proposal aims to unblock this situation not only for lincomycin biosynthesis, but generally for all above mentioned groups of bioactive natural products with biotechnological potential.
结构不同且功能多样的天然化合物——抗肿瘤药物吡咯并[1,4]苯二氮䓬、细菌激素霍马霉素以及林可酰胺类抗生素林可霉素——都有一个共同的结构单元,即4-烷基-L-脯氨酸衍生物(APD)。APD由L-酪氨酸通过一条特殊的生物合成途径产生。然而,其普遍接受的合成方案与当前的知识状态不符。基于基因失活实验以及重组酶的体外功能测试,我们为林可霉素生物合成模型设计了一种新的APD生物合成方案。在新方案中,五个最终生物合成步骤中的每一步至少有一个特征发生了变化:反应顺序、酶的分配和/或反应机制。首先,我们证明LmbW甲基化的底物与之前假设的不同。其次,我们为下一步提出了一种独特的反应机制,其中假定的γ-谷氨酰转移酶LmbA通过将谷氨酸短暂附着于LmbW产物间接去除草酰基残基。这种前所未有的机制将代表由γ-谷氨酰转移酶催化的C-C键断裂的首个例子,即一种看似不适合此类活性的酶。最后,失活实验表明LmbX是一种异构酶,这表明它将其底物转化为适合LmbY还原的化合物,从而促进其随后完全转化为APD 4-丙基-L-脯氨酸。长期以来,APD生物合成的阐明一直受阻,主要是因为明显缺乏相关的C-C键裂解酶活性。我们的提议旨在不仅为林可霉素生物合成,而且总体上为所有上述具有生物技术潜力的生物活性天然产物组消除这种情况。